Akero Therapeutics Inc (AKRO NASDAQ) stock market data APIs
$53.8385
0.54(1%)
as of October 31, 2025
Try our APIs with
free plan!
Akero Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Prev. Close
53.8385
Open
54.3774
High
54.7488
Low
53.7498
52 wk Range
21.34-58.4
Market Cap
4 345 M
Shares Outstanding
80 165 K
EPS
-0.86
Beta
-0.294
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Akero Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Akero Therapeutics Inc data using free add-ons & libraries
Get Akero Therapeutics Inc Fundamental Data
Akero Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -321 457 984
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-08
- EPS/Forecast: -0.9
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Akero Therapeutics Inc News
New
Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk
Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera. Continue Reading Afficher les commentaires
Halper Sadeh LLC Encourages AL, FFWM, AKRO, HNI Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or bre...
Novo Nordisk Offers $6.5 Billion for Metsera to Challenge Pfizer
(Bloomberg) -- Danish drugmaker Novo Nordisk A/S offered to acquire obesity startup Metsera Inc. for at least $6.5 billion, seeking to trump an agreed deal with Pfizer Inc. so it can consolidate its p...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qorvo, Inc. (Nasdaq – QRVO), First Foundation Inc. (NYSE – FFWM), Akero Therapeutics, Inc. (Nasdaq – AKRO), CoreCard Corporation (NYSE – CCRD)
BALA CYNWYD, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
